JGP Global Gestao de Recursos Ltda. Has $249,000 Position in Regeneron Pharmaceuticals Inc (REGN)

JGP Global Gestao de Recursos Ltda. increased its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 10.6% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 606 shares of the biopharmaceutical company’s stock after buying an additional 58 shares during the quarter. JGP Global Gestao de Recursos Ltda.’s holdings in Regeneron Pharmaceuticals were worth $249,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Whittier Trust Co. lifted its position in Regeneron Pharmaceuticals by 195.7% during the fourth quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 45 shares in the last quarter. Rehmann Capital Advisory Group lifted its position in Regeneron Pharmaceuticals by 1,700.0% during the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 68 shares in the last quarter. AdvisorNet Financial Inc lifted its position in Regeneron Pharmaceuticals by 208.0% during the fourth quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 52 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $29,000. Finally, Captrust Financial Advisors purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $30,000. Hedge funds and other institutional investors own 66.97% of the company’s stock.

In other news, major shareholder Sanofi sold 131,115 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 12.42% of the company’s stock.

Shares of NASDAQ REGN traded down $3.68 during trading on Wednesday, reaching $340.46. The stock had a trading volume of 850,477 shares, compared to its average volume of 751,680. Regeneron Pharmaceuticals Inc has a fifty-two week low of $281.89 and a fifty-two week high of $442.00. The company has a current ratio of 4.47, a quick ratio of 3.67 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $37.69 billion, a PE ratio of 17.19, a PEG ratio of 1.29 and a beta of 1.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share for the quarter, beating the Zacks’ consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The business had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.73 billion. During the same period in the previous year, the firm posted $5.23 earnings per share. The company’s revenue was up 21.9% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals Inc will post 19.92 earnings per share for the current year.

REGN has been the topic of a number of analyst reports. Guggenheim upgraded Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $461.00 price objective on the stock in a research report on Friday, January 4th. Zacks Investment Research cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 5th. Cowen reissued a “hold” rating and set a $385.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, January 7th. BidaskClub raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 7th. Finally, TheStreet raised Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, January 17th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and an average price target of $413.94.

WARNING: This piece was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/jgp-global-gestao-de-recursos-ltda-has-249000-position-in-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: What is the Rule of 72?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.